Posted on 03/13/2024 3:04:57 PM PDT by ConservativeMind
Endocrinologists typically look forward to the end of the Honeymoon period as it makes it difficult to formulate the proper insulin doses necessary to help the patient accurately match the carbohydrates in the food they ingest, thereby to balance and maintain desired levels of free glucose in the blood.
“We previously reported1 that ergocalciferol significantly decreased circulating tumor necrosis factor (TNF)-α and temporal trends in both hemoglobin A1c (HbA1c) and insulin dose–adjusted A1c (IDAA1c), a marker of PR, compared with placebo.”
D2 seems an odd choice. D3 seems to also show promise:
“A relationship between type 1 diabetes mellitus and vitamin D deficiency has been reported.5,6 The prevalence of vitamin D deficiency in patients with type 1 diabetes was 15% to 90.6%.7–9 There is evidence that vitamin D is important in the prevention of islet cell death and might be useful in improving the survival of islet cell grafts, and it improves the production of insulin. Low vitamin D levels were shown to have a negative effect on beta-cell function.3,4 Regular doses of vitamin D early in life have been shown to reduce the risk of developing type 1 diabetes.5 Vitamin D treatment has also been shown to improve glycemic control and insulin sensitivity in people with type 1 and type 2 diabetes and in normal individuals. Increasing vitamin D levels from 25 to 75 nmol/L results in a 60% improvement in insulin sensitivity.3,4,10–12 These effects have been mainly attributed to the immunomodulatory actions of vitamin D.5...
...The patients in our study were repleted with vitamin D3, and using up to 4000 IU of vitamin D3 to reverse states of deficiency was found to be safe.”
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2994161/
https://diabetes.org/food-nutrition/diabetes-vitamins-supplements/low-vitamin-d-insulin-resistance
“We describe here the cases of two young women who presented with positive glutamic acid decarboxylase (GAD) antibody and classic clinical manifestations of T1DM. Both patients had a prior history of Hashimoto’s thyroiditis. They were initially treated with a basal-bolus regimen of insulin (glargine and lispro/glulisine). Once their blood glucose levels were controlled, they were started on oral sitagliptin 100 mg and vitamin D3 5000 IU daily. After this therapy, both patients achieved clinical diabetes remission for 4 years, along with a decrease in anti-GAD antibody levels. These benefits were probably associated with immunological effects of these medications. Inhibition of dipeptidyl peptidase 4 (DPP-4) in animal models deregulates Th1 immune response, increases secretion of Th2 cytokines, activates CD4+CD25+FoxP3+ regulatory T-cells and prevents IL-17 production. Vitamin D3 also activates CD4+CD25+FoxP3+ regulatory T-cells, and these medications combined can improve the immune response in patients with new-onset T1DM and probably promote sustained clinical remission.”
https://edm.bioscientifica.com/view/journals/edm/2016/1/EDM16-0099.xml
Disclaimer: Opinions posted on Free Republic are those of the individual posters and do not necessarily represent the opinion of Free Republic or its management. All materials posted herein are protected by copyright law and the exemption for fair use of copyrighted works.